Clinical efficacy of Thrombomodulin alfa in hematological malignancy with disseminated intravascular coagulatio
Phase 3
- Conditions
- hematological malignancies with DIC showing decreasing fibrinogen (100mg/dl)
- Registration Number
- JPRN-UMIN000006738
- Lead Sponsor
- Saitama Medical Center, Saitama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1) the patients with severe bleeding such as brain, lung, and digestive tract 2) the patients with history of anaphylaxis to the contents in thrombomodulin alfa 3) 4) the inappropriate patients decided by the physicians
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method time-dependent change regarding DIC score, clinical manifestation, data of coagulation, PDMP, and HMGB1
- Secondary Outcome Measures
Name Time Method clinical outcome, total dose of transfusion (RCC, platelet, and FFP), adverse events during observation duration